Report Detail
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Global Clinical Trials Review, H2, 2019
- RnM3864449 |
- 10 January, 2020 |
- Global |
- 304 Pages |
- GlobalData |
- Pharma & Healthcare
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Global Clinical Trials Review, H2, 2019
Summary
GlobalData's clinical trial report, “Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Global Clinical Trials Review, H2, 2019" provides an overview of Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) clinical trials scenario. This report provides top line data relating to the clinical trials on Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) . Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Reasons to buy
- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Table of Contents
List of Tables 4
List of Figures 5
Report Guidance 6
GlobalData Clinical Trials Report Coverage 7
Clinical Trials by Region 8
Clinical Trials and Average Enrollment by Country 9
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 12
Top Five Countries Contributing to Clinical Trials in Europe 13
Top Countries Contributing to Clinical Trials in North America 14
Top Countries Contributing to Clinical Trials in Middle East and Africa 15
Top Five Countries Contributing to Clinical Trials in Central and South America 16
Clinical Trials by G7 Countries: Proportion of Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) to Metabolic Disorders Clinical Trials 17
Clinical Trials by Phase in G7 Countries 18
Clinical Trials in G7 Countries by Trial Status 19
Clinical Trials by E7 Countries: Proportion of Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) to Metabolic Disorders Clinical Trials 20
Clinical Trials by Phase in E7 Countries 21
Clinical Trials in E7 Countries by Trial Status 22
Clinical Trials by Phase 23
In Progress Trials by Phase 24
Clinical Trials by Trial Status 25
Clinical Trials by End Point Status 26
Subjects Recruited Over a Period of Time 27
Clinical Trials by Sponsor Type 28
Prominent Sponsors 29
Top Companies Participating in Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials 30
Prominent Drugs 31
Latest Clinical Trials News on Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) 32
Nov 11, 2019: Amgen highlights data to be presented on Repatha at AHA 2019 Across Cardiovascular Portfolio 32
Nov 06, 2019: The Medicines company to present inclisiran data from ORION-9 and ORION-10 pivotal phase 3 clinical studies at American Heart Association Scientific Sessions 2019 33
Sep 17, 2019: Arrowhead reports initial data for cardiometabolic candidates 33
Sep 16, 2019: Arrowhead Pharmaceuticals presents initial top-line clinical data and preclinical data on RNAi Candidate ARO-APOC3 34
Clinical Trial Profile Snapshots 35
Appendix 303
Abbreviations 303
Definitions 303
Research Methodology 304
Secondary Research 304
About GlobalData 305
Contact Us 305
Source 306
Summary:
Get latest Market Research Reports on Familial Hypercholesterolemia (Type II Hyperlipoproteinemia). Industry analysis & Market Report on Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) is a syndicated market report, published as Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Global Clinical Trials Review, H2, 2019. It is complete Research Study and Industry Analysis of Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
